Last reviewed · How we verify

Comirnaty Original/Omicron BA.4-5 — Competitive Intelligence Brief

Comirnaty Original/Omicron BA.4-5 (Comirnaty Original/Omicron BA.4-5) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Immunology / Infectious Disease.

marketed mRNA vaccine SARS-CoV-2 spike protein (original strain and Omicron BA.4-5 variants) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Comirnaty Original/Omicron BA.4-5 (Comirnaty Original/Omicron BA.4-5) — Jules Bordet Institute. This bivalent mRNA vaccine encodes spike proteins from the original SARS-CoV-2 strain and the Omicron BA.4-5 variants to elicit adaptive immune responses against multiple circulating viral lineages.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Comirnaty Original/Omicron BA.4-5 TARGET Comirnaty Original/Omicron BA.4-5 Jules Bordet Institute marketed mRNA vaccine SARS-CoV-2 spike protein (original strain and Omicron BA.4-5 variants)
BNT162b2 Bivalent (WT/OMI BA.1) bnt162b2-bivalent-wt-omi-ba-1 Pfizer marketed mRNA vaccine SARS-CoV-2 spike protein
bivalent BNT162b2 (original/Omi BA.4/BA.5) bivalent-bnt162b2-original-omi-ba-4-ba-5 Pfizer marketed mRNA vaccine SARS-CoV-2 virus
Comirnaty Omicron XBB.1.5 Comirnaty Omicron XBB.1.5 Jules Bordet Institute marketed mRNA vaccine SARS-CoV-2 spike protein (XBB.1.5 variant)
Pfizer-COVID-19 Vaccine Pfizer-COVID-19 Vaccine National Heart, Lung, and Blood Institute (NHLBI) marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
COMIRNATY - BioNTech Manufacturing GmbH COMIRNATY - BioNTech Manufacturing GmbH Jens D Lundgren, MD marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
mRNA-1283 mRNA-1283 ModernaTX, Inc. marketed mRNA vaccine HPV16 and HPV18 antigens (E6 and E7 proteins)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

  1. Pfizer · 12 drugs in this class
  2. ModernaTX, Inc. · 11 drugs in this class
  3. BioNTech SE · 5 drugs in this class
  4. Jules Bordet Institute · 5 drugs in this class
  5. Tan Tock Seng Hospital · 2 drugs in this class
  6. Clover Biopharmaceuticals AUS Pty · 1 drug in this class
  7. CanSino Biologics Inc. · 1 drug in this class
  8. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  9. CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
  10. Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Comirnaty Original/Omicron BA.4-5 — Competitive Intelligence Brief. https://druglandscape.com/ci/comirnaty-original-omicron-ba-4-5. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: